23:25 , Oct 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Gram-negative bacterial infection In silico , in vitro and mouse studies identified an oxazolidinone-based LpxC inhibitor that could help treat Gram-negative bacterial infections. In silico screening of analogs of an indazole-based LpxC inhibitor, followed...
16:20 , Jun 20, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Pseudomonas; pneumonia In vitro and mouse studies identified a hydroxamate-based LpxC inhibitor that could help treat Pseudomonas aeruginosa infections. Chemical synthesis and in vitro testing of hydroxamate analogs identified a compound that inhibited P....
01:01 , Apr 28, 2017 |  BC Innovations  |  Finance

1Q17 public-private partnership roundup

This quarter’s deal-making in public-private partnerships (PPPs) picked up from the slow rate in the second half of last year, with 1Q17 activity comparable to that seen at the start of last year. Led by...
08:00 , Feb 18, 2008 |  BC Week In Review  |  Clinical News

Abiraterone acetate: Additional Phase I/II data

Additional data from the Phase II portion of the Phase I/II COU-AA-001 trial in 44 evaluable patients showed that daily doses of CB7630 produced PSA declines of >50% and >90% in 27 and 11 patients,...